JP2021519100A5 - - Google Patents
Info
- Publication number
- JP2021519100A5 JP2021519100A5 JP2020552716A JP2020552716A JP2021519100A5 JP 2021519100 A5 JP2021519100 A5 JP 2021519100A5 JP 2020552716 A JP2020552716 A JP 2020552716A JP 2020552716 A JP2020552716 A JP 2020552716A JP 2021519100 A5 JP2021519100 A5 JP 2021519100A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- antigen
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1804860.3 | 2018-03-27 | ||
| GBGB1804860.3A GB201804860D0 (en) | 2018-03-27 | 2018-03-27 | CD47 Binding agents |
| GBGB1813693.7A GB201813693D0 (en) | 2018-03-27 | 2018-08-22 | CD47 binding agents |
| GB1813693.7 | 2018-08-22 | ||
| PCT/EP2019/057723 WO2019185717A1 (en) | 2018-03-27 | 2019-03-27 | Cd47 binding agents |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021519100A JP2021519100A (ja) | 2021-08-10 |
| JPWO2019185717A5 JPWO2019185717A5 (https=) | 2022-04-05 |
| JP2021519100A5 true JP2021519100A5 (https=) | 2022-04-05 |
| JP7458569B2 JP7458569B2 (ja) | 2024-04-01 |
Family
ID=62068079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552716A Active JP7458569B2 (ja) | 2018-03-27 | 2019-03-27 | Ｃｄ４７結合剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12421310B2 (https=) |
| EP (1) | EP3774886A1 (https=) |
| JP (1) | JP7458569B2 (https=) |
| KR (2) | KR102929571B1 (https=) |
| CN (1) | CN111936515B (https=) |
| AU (2) | AU2019246401B2 (https=) |
| CA (1) | CA3093777A1 (https=) |
| GB (2) | GB201804860D0 (https=) |
| IL (1) | IL277343B1 (https=) |
| SG (1) | SG11202008965SA (https=) |
| WO (1) | WO2019185717A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3668897B1 (en) | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN114761041A (zh) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | Hiv疫苗及其制备和使用方法 |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| US12071481B2 (en) | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4637749B2 (ja) | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗ｃｄ４７抗体 |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CN101231382B (zh) | 2008-02-26 | 2010-09-01 | 上海激光等离子体研究所 | 用于啁啾脉冲放大的光谱调制整形装置 |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| CA2967379A1 (en) * | 2014-11-18 | 2016-05-26 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| WO2016109415A1 (en) * | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| BR112018005322A2 (pt) * | 2015-09-18 | 2018-12-11 | Arch Oncology, Inc. | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| EP3747906A1 (en) * | 2016-01-11 | 2020-12-09 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| AU2017250809B2 (en) | 2016-04-15 | 2024-02-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer |
| EP3668897B1 (en) | 2017-08-18 | 2024-06-05 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
-
2018
- 2018-03-27 GB GBGB1804860.3A patent/GB201804860D0/en not_active Ceased
- 2018-08-22 GB GBGB1813693.7A patent/GB201813693D0/en not_active Ceased
-
2019
- 2019-03-27 CA CA3093777A patent/CA3093777A1/en active Pending
- 2019-03-27 SG SG11202008965SA patent/SG11202008965SA/en unknown
- 2019-03-27 KR KR1020207029435A patent/KR102929571B1/ko active Active
- 2019-03-27 US US17/041,100 patent/US12421310B2/en active Active
- 2019-03-27 AU AU2019246401A patent/AU2019246401B2/en active Active
- 2019-03-27 JP JP2020552716A patent/JP7458569B2/ja active Active
- 2019-03-27 CN CN201980021901.XA patent/CN111936515B/zh active Active
- 2019-03-27 KR KR1020267004860A patent/KR20260036010A/ko active Pending
- 2019-03-27 EP EP19715427.1A patent/EP3774886A1/en active Pending
- 2019-03-27 WO PCT/EP2019/057723 patent/WO2019185717A1/en not_active Ceased
- 2019-03-27 IL IL277343A patent/IL277343B1/en unknown
-
2025
- 2025-04-29 US US19/192,994 patent/US20260015420A1/en active Pending
-
2026
- 2026-01-29 AU AU2026200633A patent/AU2026200633A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519100A5 (https=) | ||
| JPWO2019185717A5 (https=) | ||
| JPWO2019155067A5 (https=) | ||
| JP2021515541A5 (https=) | ||
| JP2021516537A5 (https=) | ||
| JP2025000787A5 (https=) | ||
| JP2021515542A5 (https=) | ||
| JP2020531048A5 (https=) | ||
| RU2020109544A (ru) | Связывающие агенты | |
| JP2020504076A5 (https=) | ||
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| JP2021515544A5 (https=) | ||
| CN105384818B (zh) | 抗人Delta like 4单克隆抗体及其应用 | |
| JP2017149720A5 (https=) | ||
| JP2018506961A5 (https=) | ||
| JP2020514277A5 (https=) | ||
| JPWO2019224717A5 (https=) | ||
| JP2020534351A5 (https=) | ||
| JP2020521504A (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2013520984A5 (https=) | ||
| HRP20250523T1 (hr) | Pd1 i vegfr2 sredstva za dvostruko vezivanje | |
| JP2020522488A5 (https=) | ||
| JP2020513759A5 (https=) | ||
| RU2019125975A (ru) | Связывающие агенты | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний |